Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas - Test2 - elhamkhani - TriplyDB

Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas

Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas

http://www.wikidata.org/entity/Q24669579

about

HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis Molecular biology of lung cancer: clinical implications Mesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3 Lung cancer signatures in plasma based on proteome profiling of mouse tumor models Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer Cancer Stem Cells and Macrophages: Implications in Tumor Biology and Therapeutic Strategies The Role of the Transcriptional Regulation of Stromal Cells in Chronic Inflammation Targeting the tumor microenvironment: JAK-STAT3 signaling Role of interleukin-6 in Barrett's esophagus pathogenesis Berberine Inhibits Invasion and Metastasis of Colorectal Cancer Cells via COX-2/PGE2 Mediated JAK2/STAT3 Signaling Pathway Mechanism for activation of mutated epidermal growth factor receptors in lung cancer Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.Immunity, Inflammation, and Cancer The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice STAT3 negatively regulates thyroid tumorigenesis Identification of Biomarker and Co-Regulatory Motifs in Lung Adenocarcinoma Based on Differential Interactions Serum level of CC-chemokine ligand 18 is increased in patients with non-small-cell lung cancer and correlates with survival time in adenocarcinomas Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling STATs in cancer inflammation and immunity: a leading role for STAT3 IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer Nitric oxide is a key component in inflammation-accelerated tumorigenesis.Inhibition of STAT3 by niclosamide synergizes with erlotinib against head and neck cancer.Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas.Differential baseline and response profile to IFN-gamma gene transduction of IL-6/IL-6 receptor-alpha secretion discriminate primary tumors versus bone marrow metastases of nasopharyngeal carcinomas in culture.IL-12 can target human lung adenocarcinoma cells and normal bronchial epithelial cells surrounding tumor lesions.Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells.Endothelial cell-derived interleukin-6 regulates tumor growth.The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.Ovarian cancer cell heparan sulfate 6-O-sulfotransferases regulate an angiogenic program induced by heparin-binding epidermal growth factor (EGF)-like growth factor/EGF receptor signaling Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance.Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer.Deregulated EGFR signaling during lung cancer progression: mutations, amplicons, and autocrine loops.Inflammation: The Common Pathway of Stress-Related Diseases.Early administration of IL-6RA does not prevent radiation-induced lung injury in mice JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling A high-affinity protein binder that blocks the IL-6/STAT3 signaling pathway effectively suppresses non-small cell lung cancer.Inhibitory effect of ent-Sauchinone on amyloidogenesis via inhibition of STAT3-mediated NF-κB activation in cultured astrocytes and microglial BV-2 cells

P2860

Q24598092-B0603058-A683-45C3-B30F-012F8A30DAFE Q24610335-962C3C7E-AD83-4B6C-9CCA-0E24073D9AF3 Q24622968-99F65370-4203-44DC-A7BF-0CBF5F3765D7 Q24628852-1C9A6ACC-8AB2-4B45-9DBA-ED79414EB94A Q26738539-47A66718-0453-49EE-B81B-8FD3972823A7 Q26765342-3B0257F1-485A-4F64-BC80-783AC3C8349F Q26778930-C0810D58-BF91-44D9-9E84-74A9F8B210C7 Q26825658-20994FDC-120F-4507-B599-A9C5DDDBACA6 Q27009263-810D37F4-ACB0-483E-9DDC-D9F527A6B857 Q27309703-4E33F655-FC9E-4E02-87FE-A1BD8B34A2F5 Q27679902-858DFADA-C2D7-4681-8897-CDBCC3B83D06 Q27853339-839FC13D-F766-40AF-9E96-ED656954B891 Q27861048-953B2616-F93E-49B9-9FD2-2ABD9BF64459 Q28115840-50B34AF5-A4AE-4115-9D98-158CA21DD08D Q28259999-E733087A-FFB0-42EE-BDA1-0A9E6DDB6173 Q28385532-110CD145-9370-4E23-A0E4-402CD3E9DDDB Q28505424-B605C3A3-D6C6-452A-A10E-1E58CB3E0813 Q28548412-95409BFB-F503-4F12-B057-F7694C0563C7 Q28728826-84B2DEA0-D16D-43B7-B4FF-4C5AA09C4603 Q28741023-BD981EC0-C801-4962-82A4-761E527515B5 Q29547203-32308048-F66E-49F3-B320-6390CF8241B0 Q29614594-17ECE1DB-DD2B-44F7-A6A7-E069FBF72947 Q30438755-2FE8C57D-572D-4860-AF72-03938227FB79 Q31138064-E6FC73AE-1B80-4B1E-8D47-47F6EEA38E86 Q33332189-2DB1D12F-DF1A-435E-AA88-DF37F50F6B59 Q33460760-C1AEEB07-2AA1-431E-97CE-6FDBEC326220 Q33479161-4C93668D-CEAD-4EB0-AE32-5429728286D7 Q33588841-3652D660-FBB2-4525-857C-441C1DC3E887 Q33592677-9E915EEB-8F03-4650-A7A9-0FC309DB9A5A Q33613105-E91E563A-1EB3-4EC3-9AD7-969BB8496040 Q33614314-DDE20C71-2A9A-43BB-8669-AC920F16367E Q33675726-CC6E4DE2-0A30-4ACA-8001-775259573ECD Q33755300-421786DF-2266-4F74-A429-B63CF19B2A51 Q33756818-06DBB1CF-595D-43FD-B731-144C5745347E Q33769820-B44CADD6-876C-47D7-9682-8542157D1325 Q33813364-61656339-9934-456B-9AF7-A689525DF6C9 Q33828652-40357E56-535B-4079-8BB3-8ADADC54B552 Q33854898-885DA9E6-357D-4373-AD8C-CD87FD68072D Q33870701-48937A77-CD54-48C3-B809-B101FB2C9FAD Q33877126-565BDC11-DA09-4E8B-8972-67EA7DE9D1B3

P2860

Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas

http://www.wikidata.org/entity/Q24669579

description

2007 nî lūn-bûn

@nan

2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Mutations in the EGFR kinase d ...... in human lung adenocarcinomas

@ast

Mutations in the EGFR kinase d ...... in human lung adenocarcinomas

@en

Mutations in the EGFR kinase d ...... in human lung adenocarcinomas

@nl

type

label

Mutations in the EGFR kinase d ...... in human lung adenocarcinomas

@ast

Mutations in the EGFR kinase d ...... in human lung adenocarcinomas

@en

Mutations in the EGFR kinase d ...... in human lung adenocarcinomas

@nl

prefLabel

Mutations in the EGFR kinase d ...... in human lung adenocarcinomas

@ast

Mutations in the EGFR kinase d ...... in human lung adenocarcinomas

@en

Mutations in the EGFR kinase d ...... in human lung adenocarcinomas

@nl

P1433

Q24669579-EDDF042A-541F-4D14-99A4-993EEE872E9C

P1476

Q24669579-ED748EE5-D75C-49BE-9D34-6C53FBDEAAEE

P2093

Q24669579-04850F57-2077-4E8F-AF26-34D9426C63C3

Q24669579-0E7058B7-0EC7-4D24-9AB1-7F28B0D56629

Q24669579-127CABAA-DA5C-4287-BE7F-ADBBF638D8C5

Q24669579-38213301-68D1-41EA-BE24-F3180572D2B7

Q24669579-45174C26-E02E-491F-96E3-6695A48623D5

Q24669579-7BD96A74-9FD2-4A2B-B576-CAAF20812CE2

Q24669579-87D32387-F583-4923-A599-83DB381DFBC3

Q24669579-AC63D2D4-B226-44F6-B4AB-5F7B0B05A131

Q24669579-C14DD971-657A-4167-8FCC-80B292E1902B

Q24669579-D963B90B-C711-414A-95CC-6506119AD943

P2860

Q24669579-0173124D-58A0-4BEB-AF71-4564E55B3753

Q24669579-0B3A1C0E-041B-47C8-BF91-0FF3E0F1C32B

Q24669579-108EA1B7-3700-4174-8CBC-5445A420F1A0

Q24669579-12BAA8F9-7CB4-4231-AE33-EF3C4E428DA6

Q24669579-1B5D55B9-5377-46B1-AA55-76A1CF5E2AAE

Q24669579-1BEAA82D-AC82-4938-B2F6-FFAAA19C5B5D

Q24669579-1D17BB70-7B4B-4807-91A3-045AFE25032D

Q24669579-2382E868-0292-44C1-A343-4C90CADD307F

Q24669579-2622D15B-EA60-4C0B-9878-B90472788E66

Q24669579-29437B5C-782B-4BB6-AAA1-19B97AD2DAD0

P304

Q24669579-CB1C16A1-05E2-43A6-B9FD-55FBCD6F7395

P31

Q24669579-DD3BDA13-9E15-4266-9607-7AEA2CF1D51D

P3181

Q24669579-9B324BAF-EB3D-4FD6-96FD-83B4A219E20E

P356

Q24669579-08BAF416-D205-4F2F-9DD4-C430CD7AA541

P407

Q24669579-A53B34AA-F611-4F6E-A103-0BEDFD4F0A96

P433

Q24669579-D8757CB2-07B1-4402-A157-4A365D2F313B

P478

Q24669579-2E2835FB-5814-4981-AB01-7EDBA95B3E41

P50

Q24669579-66B095FB-3083-4F44-A083-11C3581AA7A1

P577

Q24669579-EE8B2193-F41D-40BE-B8CB-112B550288D4

P5875

Q24669579-A371C5F4-2A2D-412F-8ADF-B02612101D48

P698

Q24669579-8BC491C9-0BAE-48C3-8D15-33E7859AB562

P921

Q24669579-CEA3DE4B-1C06-4959-8F81-576475665D22

P932

Q24669579-229D3757-D527-4F24-AC8B-DFD9A9AF798C

P3181

P356

P1433

Journal of Clinical Investigation

P1476

Mutations in the EGFR kinase d ...... in human lung adenocarcinomas

@en

P2093

Bayard Clarkson

http://www.w3.org/2001/XMLSchema#string

Darren Veach

http://www.w3.org/2001/XMLSchema#string

Jacqueline F Bromberg

http://www.w3.org/2001/XMLSchema#string

Kenneth Leslie

http://www.w3.org/2001/XMLSchema#string

Kevin G Mark

http://www.w3.org/2001/XMLSchema#string

Noriko Motoi

http://www.w3.org/2001/XMLSchema#string

Sizhi Paul Gao

http://www.w3.org/2001/XMLSchema#string

William Bornmann

http://www.w3.org/2001/XMLSchema#string

William D Travis

http://www.w3.org/2001/XMLSchema#string

William L Gerald

http://www.w3.org/2001/XMLSchema#string

P2860

Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor

Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line

Stats: transcriptional control and biological impact

P304

3846-56

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

355030

http://www.w3.org/2001/XMLSchema#string

P356

10.1172/JCI31871

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5788250

http://www.w3.org/2001/XMLSchema#string

P698

18060032

http://www.w3.org/2001/XMLSchema#string

P921

P932

2096430

http://www.w3.org/2001/XMLSchema#string